From the moment we launched early this year, 340B Report has been the indispensable source of independent, comprehensive news coverage and analysis of the 340B program. We put our combined six decades of 340B leadership and journalism experience to work for you, getting vital information and content that you cannot find anywhere else.
340B Report has made a big difference in a short time:
We’ve broken—and keep breaking—news about drug manufacturer restrictions on 340B drug discounts and the battle to get these discounts restored.
We were the first to report about government policies that let hospitals use 340B drugs sooner in outpatient clinics, and that cut red tape for health care providers during the COVID-19 pandemic.
We’ve alerted you about major developments in three lawsuits against HHS regarding 340B reimbursement and access to 340B pricing.
We’ve written about and analyzed major 340B-related developments in the states.
Now, key Congressional offices and other policymakers cite us in 340B-related communications, and attorneys cite us in court filings.
We’ve kept 340B Report free for as long as we can. However, to continue giving you this type of impactful, useful, educational reporting, we have to start charging for subscriptions. Beginning January 15, only paid subscribers will be able to access 340B Report.
Our 20% discount offer is available until Jan. 31, 2020, so please don’t delay.
Your subscription will help us grow, so you can stay on top of 340B and be more effective. Have questions? Please email Reshma Eggleston at email@example.com.
Publisher & Chief Executive Officer
P.S. Our new and improved e-newsletter and website will be unveiled soon. New features will include easy search functionality, additional 340B resources such as a Document Center with vital communications, an Expert Directory to find companies and firms to help you operate your 340B program and an Upcoming Events page which will be the “go to” place for educational webinars and meetings.